ERAS
Erasca IncNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage ready
Factor tilt: Momentum-tilted Mid Cap
$14.78-4.40%
Close Oct 13, 2026
- Market cap
- $4.6B
- 1 month
- -8.5%
- 3 months
- -30.5%
- 1 year
- +513.3%
- 52-week range
- $2.20$22.47
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.13Quarter to Sep 30, 2026 · 8 analysts · revenue $0
- Short interest
- 14.5% of float35.3M shares · settled Sep 30, 2026 · +7.0% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$287.22M
- Free cash flow
- -$98.08M
- Book value
- $361.87M
- Total debt
- $44.71M
- P/E
- —
- Price / sales
- —
- Price / book
- 12.7×
- FCF yield
- -2.1%
- Net margin
- —
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if ERAS is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
54 top institutions tracked
as of 2026-Q2 (filed 2026-09-23)
Last 13F trend: accumulating (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 2
Largest 13-F holders · Q2 2026
257 filers reported a long position in ERAS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | $457.5M | 25M | +1.2% |
| T. Rowe Price Investment Management, Inc. | $388.1M | 21.2M | -0.3% |
| BlackRock, Inc. | $387.5M | 21.2M | +5% |
| RTW INVESTMENTS, LP | $328.8M | 17.9M | +11.1% |
| Venrock Adviser, LLC | $327.8M | 17.9M | +9.2% |
| STATE STREET CORP | $223.2M | 12.2M | +31% |
| Logos Global Management LP | $222.6M | 12.2M | +9% |
| VANGUARD CAPITAL MANAGEMENT LLC | $208.9M | 11.4M | +1.4% |
| Siren, L.L.C. | $208.8M | 11.4M | +1.4% |
| Paradigm Biocapital Advisors LP | $175M | 9.6M | -8.1% |
Get the Full Analysis for ERAS
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.